目的 通過復制人肝癌細胞株HepG2裸鼠皮下移植瘤模型，觀察綠茶提取物表沒食子兒茶素沒食子酸酯（EGCG）干預對HepG2移植瘤新生血管生成的影響。 方法 瘤體接種復制HepG2移植瘤模型，荷瘤裸鼠20只隨機分組，實驗組給予EGCG溶液每日20 mg/（kg·只），腹腔注射3周，對照組給予等量滅菌注射用水3周，末次用藥24 h，后處死裸鼠，剝離移植瘤。常規病理切片觀察移植瘤組織結構；逆轉錄-聚合酶鏈式反應和免疫組織化學法檢測移植瘤缺氧誘導因子-1α（HIF-1α）、血管內皮生長因子（VEGF）mRNA及蛋白表達，并通過檢測CD34表達計數瘤組織微血管密度（MVD）。 結果 組織病理學觀察實驗組移植瘤見大量壞死區，瘤體內血管數量明顯少于對照組；實驗組HIF-1α、VEGF mRNA及蛋白表達水平比對照組均明顯下調（P＜0.05），實驗組MVD比對照組明顯下降（P＜0.05）。 結論 EGCG可抑制荷瘤裸鼠HepG2移植瘤新生血管生成。
ObjectiveTo explore the value of multidisciplinary team (MDT) discussion in the comprehensive treatment of HER-2 positive breast cancer.MethodThe clinical data of 2 patients with HER-2 positive breast cancer admitted to the Affiliated Hospital of Southwest Medical University after MDT discussions were analyzed retrospectively.ResultsCase 1 was a 32-year-old woman diagnosed with left breast non-special type invasive carcinoma at admission, cT2N1M0, stage ⅡB, WHO grade 2, ER (–), PR (–), HER-2 (+++), Ki-67 (+, 20%). After MDT discussion, the patient was treated with neoadjuvant chemotherapy for 6 cycles, and the efficacy evaluation was partial response, received left breast conserving surgery and axillary lymph node dissection (ALND), postoperative staging ypT1aN1ycM0, stage ⅡA, Miller-Payne grade 4, the patient was satisfied with the shape of breast, received radiotherapy and anti-HER-2 therapy after surgery. At present, there was no recurrence and metastasis during anti-HER-2 therapy. Case 2 was diagnosed with right breast non-special type invasive carcinoma at admission, cT3N0M0, stage ⅡB, WHO grade 3, ER (–), PR (–), HER-2 (+++), Ki-67 (+, 40%), local advanced breast cancer. After MDT discussion, the patient was treated with neoadjuvant chemotherapy for 2 cycles, and the efficacy evaluation was progressive disease. After the replacement of two neoadjuvant chemotherapy regimen, the efficacy evaluation was still progressive disease. Finally after MDT discussion, the patient received right breast mastectomy and ALND, postoperative staging ypT4bN1ycM0, stage ⅢB, Miller-Payne grade 1, received radiotherapy, adjuvant treatment with pyrotinib and capecitabine after surgery. The patient was followed up for 3 months by telephone, the patient did not follow the doctor’ instructions, no recurrence and metastasis was found in the review.ConclusionUnder the precision medical system, comprehensive treatment of breast cancer based on the MDT model could target patients’ disease characteristics, physical conditions, previous diagnosis and treatment, family situation, and other individual factors, formulate the best personal treatment plan for patients, and bring greater benefits to patients.